As per DelveInsight, the Metastatic Merkel Cell Carcinoma Market Size is anticipated to increase in the coming years owing to the rise in the number of incident population of Metastatic Merkel Cell Carcinoma patients in the 7MM. Extensive R&D activities by academia and industries and the expected launch of therapies will also fuel the market’s growth.
Several of the therapies are in development by major pharma giants and are expected to launch in the coming years. Currently, Incyte has its Metastatic Merkel Cell Carcinoma drug candidates in the most advanced stage of clinical development.
DelveInsight’s “Metastatic Merkel Cell Carcinoma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Metastatic Merkel Cell Carcinoma Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Metastatic Merkel Cell Carcinoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Metastatic Merkel Cell Carcinoma: An Overview
Merkel Cell Carcinoma (MCC) is a rare, highly aggressive neuroendocrine cutaneous neoplasm with a variable clinical presentation. It is a predominantly dermal-based lesion composed of monotonous small round cells with scanty cytoplasm, often difficult to differentiate from small round cell tumors, metastatic small cell carcinoma, blastic hematologic malignancies, and melanoma.
It is caused by ultraviolet (UV) light exposure, infection with the HIV virus, autoimmune diseases (rheumatoid arthritis), and certain malignancies like chronic lymphocytic leukemia or lymphomas, which can profoundly suppress the immune system and may act as a causative agent in MCC. It is also associated with Merkel cell polyomavirus in more than 80% of cases.
Treatment of stage IV Merkel cell carcinoma may include the following: Immunotherapy (immune checkpoint inhibitor therapy using avelumab or pembrolizumab). Chemotherapy, surgery, or radiation therapy as palliative treatment to relieve symptoms and improve quality of life.
Metastatic Merkel Cell Carcinoma Market Key Facts
-
As per DirkSchadendorf et al. (2016), In a study of over 14,000 patients, 50.6% of patients presented with local disease, 35.4% with nodal disease, and 13.5% with distant metastatic MCC were observed.
-
As per the study conducted by Kelly G. Paulson et al. (2017), Merkel cell carcinoma (MCC) is a neuroendocrine skin cancer with high metastatic potential, with one-third to one-half of patients developing recurrence or metastasis.
-
As per the National Organization for Rare Disorders 2019: Approximately 60% of MCC tumors arise in men. In the past 15 years, the incidence has tripled in the United States, and it can be lethal for about one-third of the people affected.
-
As of 2015, approximately 2500 persons per year are diagnosed with this cancer in the United States.
Metastatic Merkel Cell Carcinoma Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Metastatic Merkel Cell Carcinoma market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Metastatic Merkel Cell Carcinoma market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Metastatic Merkel Cell Carcinoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.
Metastatic Merkel Cell Carcinoma Epidemiology Segmentation
-
Total Incident Population of Merkel Cell Carcinoma
-
Gender-specific Cases of Metastatic Merkel Cell Carcinoma
-
Incident Population of Metastatic Merkel Cell Carcinoma
-
Diagnosed and Treatable cases of Metastatic Merkel Cell Carcinoma
Metastatic Merkel Cell Carcinoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic Merkel Cell Carcinoma market or expected to get launched during the study period. The analysis covers Metastatic Merkel Cell Carcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Metastatic Merkel Cell Carcinoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How Metastatic Merkel Cell Carcinoma Market Will Evolve by 2032 @
https://www.delveinsight.com/sample-request/metastatic-merkel-cell-carcinoma-market
Metastatic Merkel Cell Carcinoma Therapeutics Analysis
Globally, various companies are involved in developing effective therapies for Metastatic Merkel Cell Carcinoma, and further progress in the research and development is likely to translate into a real improvement in the treatment options for Metastatic Merkel Cell Carcinoma in the coming years.
Some of the key companies in the Metastatic Merkel Cell Carcinoma Therapeutics Market include:
• Incyte Corporation
• Transgene
• Ocellaris Pharma
• Roche
• Exelixis
• Sensei Biotherapeutics
• Checkmate Pharmaceuticals
• SOTIO Biotech
• Merck
• Morphogenesis
• NantKwest
• Kartos Therapeutics
And many others
Metastatic Merkel Cell Carcinoma Therapies covered in the report include:
• IFx-Hu2.0
• Nivolumab + Ipilimumab
• INCMGA00012
• haNk and aNK cell therapies
And many more.
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More –
https://www.delveinsight.com/sample-request/metastatic-merkel-cell-carcinoma-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Metastatic Merkel Cell Carcinoma Competitive Intelligence Analysis
4. Metastatic Merkel Cell Carcinoma Market Overview at a Glance
5. Metastatic Merkel Cell Carcinoma Disease Background and Overview
6. Metastatic Merkel Cell Carcinoma Patient Journey
7. Metastatic Merkel Cell Carcinoma Epidemiology and Patient Population (In US, EU5, and Japan)
8. Metastatic Merkel Cell Carcinoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Metastatic Merkel Cell Carcinoma Unmet Needs
10. Key Endpoints of Metastatic Merkel Cell Carcinoma Treatment
11. Metastatic Merkel Cell Carcinoma Marketed Products
12. Metastatic Merkel Cell Carcinoma Emerging Drugs and Latest Therapeutic Advances
13. Metastatic Merkel Cell Carcinoma Seven Major Market Analysis
14. Attribute Analysis
15. Metastatic Merkel Cell Carcinoma Market Outlook (In US, EU5, and Japan)
16. Metastatic Merkel Cell Carcinoma Access and Reimbursement Overview
17. KOL Views on the Metastatic Merkel Cell Carcinoma Market
18. Metastatic Merkel Cell Carcinoma Market Drivers
19. Metastatic Merkel Cell Carcinoma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
https://www.delveinsight.com/sample-request/metastatic-merkel-cell-carcinoma-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
“Hyperammonemia Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Hyperammonemia Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/